Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement.

MLA

Schlaich, Markus P., et al. “Targeting the Sympathetic Nervous System with the Selective Imidazoline Receptor Agonist Moxonidine for the Management of Hypertension: An International Position Statement.” Journal of Hypertension, vol. 42, no. 12, Dec. 2024, pp. 2025–40. EBSCOhost, https://doi.org/10.1097/HJH.0000000000003769.

APA

Schlaich, M. P., Tsioufis, K., Taddei, S., Ferri, C., Cooper, M., Sindone, A., Borghi, C., Parissis, J., Marketou, M., Vintila, A. M., Farcas, A., Kiuchi, M. G., & Chandrappa, S. (2024). Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement. Journal of Hypertension, 42(12), 2025–2040. https://doi.org/10.1097/HJH.0000000000003769

Chicago

Schlaich, Markus P, Konstantinos Tsioufis, Stefano Taddei, Claudio Ferri, Mark Cooper, Andrew Sindone, Claudio Borghi, et al. 2024. “Targeting the Sympathetic Nervous System with the Selective Imidazoline Receptor Agonist Moxonidine for the Management of Hypertension: An International Position Statement.” Journal of Hypertension 42 (12): 2025–40. doi:10.1097/HJH.0000000000003769.